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36 H.E. Saadany et al.Aim of the work: To evaluate the relation between asymmetric dimethylarginine (ADMA), high
sensitive C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1) (both serum
levels and the genotypes of the MCP-1 A2518G polymorphism) with the development of carotid
atherosclerosis in patients with SLE and their relation to disease activity.
Patients and methods: In the present study, 30 non-menopause SLE female patients and 20 healthy
age-matched females were included. Both patients and controls were subjected to evaluation of
body mass index (BMI), IMT, serum glucose, serum lipids, hs-CRP, ADMA, MCP-1 (both serum
level and gene polymorphism). Serum ADMA, hs-CRP, and MCP-1, levels were measured by
enzyme-linked immunosorbent assay. MCP-1 genomic variants were detected by polymerase chain
reaction followed by restriction enzyme–fragment analysis.
Results: Values for IMT, hs-CRP, ADMA and MCP-1 were signiﬁcantly higher in patients with
SLE than in healthy controls with more signiﬁcant increase in SLE patients with IMTP1 mm than
in those with IMT <1 mm. Carotid IMT was signiﬁcantly positively correlated with all the studied
variables except for age, BMI and FBS, but signiﬁcantly negatively correlated with HDL-C in all
SLE patients. G/G genotype of MCP-1 A2518G gene was more frequent in SLE patients than
controls. IMT, hs-CRP, ADMA and MCP-1 from patients with G/G phenotypes were markedly
higher than those from patients with the A/A genotype.
In multiple regression analysis, ADMA and MCP-1 were the strongest independent determinants
of IMT in SLE patients.
Conclusions: Assessment of high levels of ADMA, hs-CRP, MCP-1, in addition to the MCP-1
A2518G polymorphism may play a role in the pathogenesis of accelerated atherosclerosis in
SLE patients and would be useful in identifying the risk of developing cardiovascular disease.
Kindly suggest: Development of a novel therapy targeting ADMA and MCP-1 may have a
potential role in preventing the progression of increased IMT in SLE patients.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is a multi-system autoim-
mune disease with a complex pathogenesis involving multiple
genetic and environmental factors [1]. It is associated with an in-
creased risk of atherosclerosis and related cardiovascular disease
[2]. The mechanisms underlying the accelerated atherosclerosis
in SLEare not clear because the traditional risk factors fail to ac-
count fully for the excess of cardiovascular events in lupus pa-
tients [3]. Therefore, it has been suggested that patients with
SLE possess additional risks in addition to the traditional risk
factors for the development of accelerated atherosclerosis [4].
Because atherosclerosis is a systemic disease, there is strong
correlationbetween coronary atherosclerosis and that in the car-
otid arteries. Intima–media thickness (IMT) is a non-invasive
predictor of early arterial wall alteration, which identiﬁes and
quantiﬁes early structural vascular abnormalities and is cur-
rently considered as a marker of premature atherosclerosis [5].
Endothelial dysfunction may play pivotal roles in the initi-
ation, progression and propagation of the atherosclerotic pro-
cess [2]. Asymmetric dimethylarginine (ADMA) is the major
endogenous inhibitor of nitric oxide synthase (NOS), the
enzyme which synthesizes nitric oxide (NO) which has anti-
atherosclerotic properties [6]. Increased plasma ADMA con-
centration causes impaired NO synthesis leading to endothelial
dysfunction and atherosclerotic vascular disease [7].
Since atherosclerosis in part may be an inﬂammatory dis-
ease, circulating factors related to inﬂammation may be predic-
tors of cardiovascular disease [8].
High sensitive C-reactive protein (hs-CRP) is secreted by
several cell types in inﬂammatory microenvironments, such
as rheumatoid synovium and atherosclerotic lesions, induces
the production of inﬂammatory cytokines from monocytes,and promotes monocyte chemotaxis [9]. It has been associated
with increased IMT and suggested to cause initiation and pro-
gression of atherosclerosis [10].
Monocyte chemoattractant protein-1 (MCP-1) is a B-
chemokine responsible formonocyte and lymphocytesT recruit-
ment in acute inﬂammatory conditions andmaybe an important
mediator in chronic inﬂammation; it also proposed that it is
responsible for tissue inﬂammation in autoimmune diseases
[11]. It was found to be highly expressed in human atheroscle-
rotic plaques and postulated to have a crucial role in monocyte
recruitment into the sub-endothelial lesions [12], so that mice
deﬁcient for MCP-1 develop less atherosclerosis. On the basis
of this evidence, MCP-1 should be considered a potent athero-
sclerotic factor and a target for selective therapies [13].
A biallelic A/G polymorphism has been found in the MCP-
1 distal gene regulatory region at position 2518 that affects
the level of MCP-1 expression in response to an inﬂammatory
stimulus. The effect of the G allele appears to be dose depen-
dent as cells from individuals homozygous for G at 2518 pro-
duced more MCP-1 than cells from G/A heterozygotes [14].
The aim of this study was to evaluate the relation between
ADMA, hs-CRP, MCP-1 (both serum levels and the genotypes
of the MCP-1 A2518G polymorphism) with the development
of carotid atherosclerosis in SLE patients and their relation to
disease activity.
2. Materials and methods
A total of 30 premenopausal SLE female patients and 20 age
and sex matched healthy controls were enrolled in this study.
All patients were fulﬁlling the latest version of the American
College of Rheumatology (ACR) revised criteria for the classi-
ﬁcation of SLE [15]. The disease activity was assessed using the
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selected from out-patient clinic of Rheumatology and Rehabil-
itation Department of Tanta University Hospital. Written in-
formed consent was obtained from all participants.
2.1. Exclusion criteria include
In order to avoid confusion with other known risk factors for
atherosclerosis, the exclusion criteria were: clinically evident
atherosclerosis, hypertension, or the use of antihypertensive
medication; hyperlipidaemia, or the use of lipid-lowering medi-
cation; diabetes mellitus, and a history of ischaemic heart dis-
eases or cerebrovascular events, infections in the previous
4 weeks, pregnancy or lactation in the previous 6 weeks, renal
failure and age <18 or >65 years. Smoking habits both in
SLE patients and healthy controls.
For all participants body mass index (BMI) and blood pres-
sure were assessed.
2.2. IMT of the carotid arteries
All subjects underwent B-mode ultrasonography of extracra-
nial carotid arteries using a 7.5 MHz probe which provides a
direct and non-invasive assessment of subclinical atherosclero-
sis through IMT measurement and detection of atherosclerotic
plaques. Common carotid artery (CCA), internal carotid, and
external carotid arteries were evaluated carefully on both sides.
CCA IMT measurements of the proximal and distal CCA pos-
terior wall were done. Three measurements were made in a
non-neighbouring fashion within an approximately 1 cm seg-
ment both from the left and right CCA proximal and distal
portions. IMT values were then calculated by obtaining the
arithmetic means of the measured values [5]. The mean IMT
value for each subject was calculated using the formula [(Lt
IMT+ Rt IMT)/2] and this value was taken as the measure
of current common carotid artery wall thickness [17].
Then the patients were classiﬁed into two groups with IMT
<1.0 mm (n= 17) and with IMT P1.0 mm (n= 13).
2.3. Biochemical assay
Venous blood sampling was obtained from all subjects by
puncture of an ante-cubital vein at 8 a.m. after an overnight
fasting. In order to obtain serum, blood was allowed to coag-
ulate for at least 30 min–1 h at room temperature and then
centrifuged at 3000g for 10 min at 20 C. The obtained serum
was immediately frozen at 70 C for future analysis of:
1. Total cholesterol (TC), triglyceride (TG) concentrations and
high density lipoprotein-cholesterol (HDL-C) concentration
were determined, low-density lipoprotein-cholesterol
(LDL-C) concentrations were calculated using Friedewald’s
equation (LDL-C = TC  HDL-C  TG/5).
2. Fasting blood sugar (FBS) level.
3. Serum ADMA by ELISA Kit using Immundiagnostik AG,
Stubenwald-Allee 8a, D 64625 Bensheim, according to Lu
et al. [18].
4. Serum hs-CRP by ELISA Kit using Monobind Inc., Lake
Forest, CA 92630, USA, according to Auer et al. [19].
5. Serum MCP-1 by ELISA Kit using RayBio Human MCP-1
ELISAKit Protocol according to Leonard andYoshimura [20].6. Genotyping of the MCP-1 2518 polymorphism was per-
formed as described by Rovin et al. [21]. Brieﬂy, Genomic
DNA was extracted from 200 ll of EDTA-anticoagulated
peripheral blood leukocytes using the Qiagen mini blood
DNA puriﬁcation kits (Qiagen, Canada) according to the
manufacturer’s instructions. MCP-1 genomic variants were
detected by polymerase chain reaction (PCR) followed by
restriction enzyme–fragment analysis using a PvuII
site affected by the G/A polymorphism. Ampliﬁcation
with the primers 50-CCGAGATGTTCCCAGCACAG-30
(forward) and 50-CTGCTTTGCTTGTGCCTCTT-30
(reverse) (where A is adenine, C is cytosine, G is guanine
and T is thymine) generated a 930 bp product. PCR is
performed in 50 ll volumes containing 100 ng of DNA,
250 nmol/l of deoxinucleotides triphosphates, 1.5 mmol/l
of MgCl2, 1 U of Hot Star Taq polymerase (Qiagen Inc.,
Valencia, CA), and 25 pmol/l of each primer. Cycle condi-
tions used were 95 C for 15 min, followed by 35 cycles of
94 C for 45 s, 55 C for 1 min, and 72 C for 1.5 min, with
a ﬁnal extension of 72 C for 10 min. The PCR product was
digested with 5 U of PvuII endonuclease (New England
Biolabs, Beverly, MA) and analyzed by phototyping in
2% agarose gels containing ethidium bromide. Digestion
with PvuII yields 708 bp and 222 bp fragments when G is
at position 2518. The identiﬁed genotypes were named
according to the presence or absence of the enzyme
restriction site. So, samples showing only a 930 bp band
were assigned as A/A, samples showing two bands of
708 and 222 bp were considered G/G and samples show-
ing three bands at 930, 708 and 222 bp were typed
A/G.
7. In SLE patients inﬂammatory parameters indices such as
ESR mm/1st h were determined by Westergren and CRP
was determined by semi-quantitative latex agglutination.
2.4. Statistical analysis
Statistical analysis in this study was performed using the
MINITAB 1 and SPSS version 10. Most data are expressed
as the mean (±SD) for quantitative variables and as numbers
and percentages for categorical variables. Student’s t-test was
applied to compare variables between 2 groups, whereas the
frequencies of various alleles and genotypes were compared be-
tween the groups by Fisher’s exact. For each analysis, an odds
ratio (OR) and 95% conﬁdence interval (CI) were calculated.
Pearson’s correlation analysis was used to examine the rela-
tionships between IMT and tested atherosclerotic risk factors
and between ADMA, hs-CRP and MCP-1 and other variables.
Associations between IMT and other risk factors were eval-
uated by simple regression analysis followed by multiple linear
regressions. All statistical tests were two-tailed and only a P
value < 0.05 was considered statistically signiﬁcant.3. Results
Table 1 shows the clinical, laboratory and genetic characteris-
tics of the studied groups; in the SLE group 9/30 patients
(30%) presented with an IMT <1.0 mm, while 21/30 (70%)
with an IMT P1.0 mm. In the control group, IMT P1.0 was
not detected. SLE patients with IMTP1.0 mm compared with
Table 1 Clinical, laboratory and genetics characteristics of the SLE patients and healthy controls.
Control (n= 20) SLE P1 P2 P3
<1 mm (n= 9) P1 mm (n= 21)
IMT (mm) 0.59 ± 43 0.86 ± 0.08 1.6 ± 0.02 0.096* 0.033* 0.033*
Age (years) 31.4 ± 37 28 ± 0.89 31 ± 12 0.635 0.986 0.627
Disease duration (years) 3.0 ± 1.9 6.0 ± 1.2 0.001*
BMI (kg/m2) 25.8 ± 3.1 25.8 ± 3.2 26.6 ± 3.2 0.745 0.835 0.890
ESR (mm/1st h) 9.5 ± 4.5 23.5 ± 6.3 25.5 ± 5.5 0.001 0.001 0.241
CRP (mg/L) 4.5 ± 2.3 7.5 ± 3.7 8.2 ± 2.1 0.077 0.035 0.850
FBS (mg/dL) 88.2 ± 3.1 89.5 ± 3.9 90.8 ± 3.7 0.996 0.831 0.922
TG (mg/dL) 90.3 ± 14.5 97.7 ± 11.7 100 ± 11.9 0.088 0.093 0.049
TC (mg/dL) 160.5 ± 13.7 162 ± 15.2 173.8 ± 14.1 0.452 0.040 0.038
LDL-C (mg/dL) 96.1 ± 1.7 102.9 ± 16.4 106.5 ± 15.4 0.214 0.068 0.358
HDL-C (mg/dL) 43.9 ± 5.4 36.2 ± 5.4 33.8 ± 3.7 0.235 0.068 0.029
hs-CRP (mg/L) 1.54 ± 0.48 2.5 ± 1.3 3.7 ± 0.9 0.008* 0.001* 0.069*
ADMA (lmol/L) 0.58 ± 0.05 0.65 ± 0.03 0.70 ± 0.02 0.076* 0.002* 0.352*
MCP-1 (ng/mL) 187.9 ± 535 268.7 ± 34.2 297.5 ± 35.6 0.001* 0.001* 0.008*
Genotypes GG (%) 1 (5%) 4 (44.4%) 15 (71.5%) 0.002* 0.001* 0.009*
AG (%) 6 (30%) 3 (33.3%) 5 (28.6%) 0.731 0.824 0.891
AA (%) 13 (65%) 2 (22.2%) 1 (4.7%) 0.011* 0.018* 0.001*
Alleles
A 32 (80%) 10 (55.6%) 6 (28.7%) 0.546* 0.001* 0.712*
G 8 (20%) 8 (44.4%) 35 (83.3%) 0.009* 0.004* 0.152*
BMI, body mass index; IMT, intima–media thickness; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; FBS, fasting blood sugar; hs-CRP, high sensitive-CRP; ESR, normal, <10 mm/1st h; CRP,
normal, <6 mg/l; ADMA, asymmetric dimethylarginine; hs-CRP, high sensitive C-reactive protein; and MCP-1, monocyte chemoattractant
protein-1. Data are presented as the mean (SD). P> 0.05 are presented as NS. NS = non-signiﬁcant; A = adenine; and G= guanine.
P1 comparison between controls vs. SLE patients <1 mm.
P1 comparison between controls vs. SLE patients P1 mm.
P1 comparison between SLE patients <1 mm vs. P1 mm.
* Signiﬁcance = P< 0.05.
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ences in BMI, FBS, TG, LDL-C and lower HDL-C but higher
with signiﬁcant differences in the values of disease duration,
IMT, hs-CRP, ADMA and MCP-1 serum level. In comparison
with controls values for age, BMI, FBS and lipid proﬁle were
higher (HDL-C was lowered) in both SLE groups but with
no signiﬁcant differences (except for TG and HDL-C). Both
groups of SLE patients demonstrated signiﬁcantly increased
mean carotid IMT values, serum concentrations of ADMA,
hs-CRP and MCP-1. Comparison between SLE patients and
controls as regards genotype and allele frequencies of MCP-1
2518, showed a signiﬁcant increased frequencies of MCP-1
2518 GG genotype and G allele in both SLE groups with
more signiﬁcance in patients with IMTP1.0 mm than SLE pa-
tients with an IMT <1.0 mm, on the other hand the frequency
of the A/A genotype and A allele was signiﬁcantly higher in
controls compared with both SLE groups patients with more
signiﬁcance in patients with IMTP1.0 mm than SLE patients
with an IMT<1.0 mm. No signiﬁcant difference was found be-
tween the three groups in GA genotype.
Table 2 shows signiﬁcant correlation between ADMA and
all the studied parameters except for age and FBS, but both
MCP-1 and hs-CRP are signiﬁcantly correlated with carotid
IMT and with each other.
In Table 3 simple regression analysis was carried out
using IMT as the dependent variable, and other studied
variables as independent variables. LDL-C, HDL-C,
ADMA, hs-CRP, and MCP-1 were signiﬁcantly associated
with IMT.In multiple regression analysis (Table 4), ADMA and
MCP-1 were the strongest independent determinants of IMT
in patients with SLE.
Atherosclerotic risk factors of all patients respective of
MCP-1 gene polymorphism are shown in Table 5 in which
there were signiﬁcant differences in the IMT and serum levels
of HDL-C, ADMA, hs-CRP and MCP-1 level, between the
different genotypes with the highest values (the lowest value
for HDL-C) present in those carrying the G allele (GG and
GA). Genotyping of the MCP-1 2518 polymorphism (GG,
AG and AA) is represented in Fig. 1.4. Discussion
A leading cause of morbidity and mortality in SLE patients is
represented by an increased occurrence of cerebro-vascular
and cardiovascular diseases attributable to the development
of accelerated atherosclerosis [22]. These ﬁndings highlight
the importance of recognizing and managing early stages of
atherosclerosis for effective cardiovascular prevention [5,23].
In this study, the combination of classic risk factors (BMI,
disease duration and lipid proﬁle) and altered concentrations
of ADMA, hs-CRP and MCP-1 (both serum level and gene
polymorphism) appears to explain at least part of the relation
between SLE and the change in carotid IMT.
In the current study there was no signiﬁcant difference be-
tween SLE patients and controls in most of the classical risk
factors for atherosclerosis, except for TG and HDL-C which
Table 2 Correlation between ADMA, MCP-1 and hs-CRP and other variables in SLE patients (n= 30).
Variables SLE patients (n= 30)
ADMA (lmol/l) MCP-1 (ng/ml) hs-CRP (mg/l)
r P r P r P
Age (years) 0.16 >0.05 0.18 >0.05 0.21 >0.05
Disease duration 0.43 <0.01 0.23 >0.05 0.40 >0.05
BMI (kg/m2) 0.37 <0.05 0.22 >0.05 0.37 >0.05
IMT (mm) 0.48 <0.001 0.49 <0.001 0.47 <0.001
FBS (mg/dl) 0.20 >0.05 0.19 >0.05 0.20 >0.05
TG (mg/dl) 0.38 <0.05 0.22 >0.05 0.39 >0.05
TC (mg/dl) 0.43 <0.01 0.20 >0.05 0.20 >0.05
LDL-C (mg/dl) 0.39 <0.05 0.23 >0.05 0.19 >0.05
HDL-C (mg/dl) 0.38 <0.05 0.21 >0.05 0.22 >0.05
hs-CRP (mg/l) 0.47 <0.001 0.44 <0.01 – –
ADMA (lmol/l) – – 0.48 <0.001 0.47 <0.001
MCP-1 (ng/ml) 0.48 <0.001 – – 0.44 <0.01
Anti-dsDAN 0.45 <0.001 0.37 <0.05 0.43 <0.01
Complement (C3) 0.034 <0.001 0.38 <0.05 0.48 <0.001
SLEDAI 0.544 <0.001 0.733 <0.001 0.523 <0.001
Table 3 Lipid proﬁle, hs-CRP, MCP-1 and ADMA as
predictive factors for IMT among SLE patients (simple linear
regression).
Variables SLE patients (n= 30)
Standardized B coeﬃcients T P
LDL-C (mg/dl) 0.249 2.029 0.048*
HDL-C (mg/dl) 0.292 2.112 0.040*
TG (mg/dl) 0.100 0.953 0.346
TC (mg/dl) 0.010 0.088 0.931
hs-CRP (mg/l) 0.612 5.359 0.0001*
ADMA (lmol/l) 0.480 4.079 0.0001*
MCP-1 (ng/ml) 0.361 2.724 0.009*
B = regression coefﬁcient.
* Signiﬁcance = P< 0.05.
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icant difference as regards IMT, ADMA, hs-CRP and MCP-1.
The present work together with several research groups has
shown that IMT is signiﬁcantly increased in SLE patients than
in control subjects [5–24,25], and it was signiﬁcantly correlated
with all the studied parameters except for age, BMI and FBG
as mentioned by Carotti et al. [26]. In contrast Del Sol et al.
[27] have considered that IMT would not add substantiallyTable 4 Multiple regression analysis of ADMA, MCP-1, hs-CRP, L
Variables B SE P
ADMA (lmol/l) 42.697 17.953 0.006*
MCP-1 (ng/ml) 0.044 0.016 0.026*
hs-CRP (mg/l) 4.229 2.964 0.154
LDL-C (mg/dl) 0.093 0.076 0.223
HDL-C (mg/dl) 0.731 0.440 0.097
TG (mg/dl) 0.043 0.081 0.601
TC (mg/dl) 0.045 0.088 0.612
B = logistic regression coefﬁcient.
SE = standard error of B.
* Signiﬁcance = P< 0.05.when used as a screening tool to discriminate subjects with
high and low risk of coronary heart disease.
Although the precise mechanisms of atherosclerosis remain
unclear, endothelial dysfunction and inﬂammation in addition
to genetic risk factors represent important factors in the onset
of atherosclerosis [28].
Endothelial dysfunction is a key event in atherogenesis
appearing long before the formation of a structural athero-
sclerotic lesion in SLE. Various factors may give rise to alter-
ations in vascular wall properties [29]. ADMA represents a
new and well-characterized marker that has been associated
with many traditional and novel risk factors in the setting
of atherosclerosis. This biomarker represents nitric oxide bio-
availability and also oxidative stress, thus identifying individ-
uals at high cardiovascular risk even in an early stage, apart
from traditional risk factors and inﬂammatory biomarkers
[6].
In the present study, SLE patients have increased serum
ADMA level, compared to that of control subjects with more
signiﬁcant increase in SLE patients with IMT P1.0 mm.
Moreover there was also a signiﬁcant positive correlation be-
tween IMT, disease activity and serum ADMA levels. These
came in agreement with studies of Bultink et al. [30]. High
ADMA levels in SLE may be due to a number of mechanisms:DL-C, HDL-C, TC and TG of the SLE patient regarding IMT.
Exp (B) 95% Conﬁdence interval for Exp (B)
Lower limit Upper limit
1.05 1.012 1.08
1.09 1.011 1.18
6.86 0.206 22.95
0.09 0.945 1.27
0.48 0.203 1.14
0.96 0.817 1.12
0.05 0.879 1.24
Table 5 Atherosclerotic risk factors of all SLE patients regarding MCP-1 gene polymorphism.
Variables AA (n= 9) AG (n= 10) GG (n= 11) F P value
Age (years) 42 ± 3 42 ± 2 43 ± 4 0.4 >0.05
Disease duration (years) 10.4 ± 3.3 10.6 ± 2.8 11 ± 2.8 0.12 >0.05
BMI (kg/m2) 24.9 ± 2.7 26.5 ± 3.3 27.2 ± 3.3 1.4 >0.05
IMT (mm) 0.75 ± 0.13 0.81 ± 0.11 0.92 ± 0.14 4.4 0.02*
FBS (mg/dl) 89.5 ± 4.5 89.1 ± 3.9 90.7 ± 3.4 0.5 >0.05
TG (mg/dl) 93.3 ± 12.2 99 ± 9.9 103.6 ± 16.3 1.5 >0.05
TC (mg/dl) 166.3 ± 15.9 167.9 ± 15.3 168.35 ± 15.5 0.05 >0.05
LDL-C (mg/dl) 99.05 ± 15.3 102.4 ± 17 109.9 ± 15.4 1.2 >0.05
HDL-C (mg/dl) 37.2 ± 5.1 35.8 ± 3.3 32.4 ± 3.9 3.7 0.04*
hs-CRP (mg/l) 2.2 ± 0.6 3.2. ± 1.01 3.8 ± 0.76 9.7 <0.001*
ADMA (lmol/l) 0.63 ± 0.04 0.68 ± 0.04 0.69 ± 0.03 7.9 0.002*
MCP-1 (ng/ml) 262.2 ± 31.7 274.5 ± 30.9 307.7 ± 51.7 3.5 0.04*
* Signiﬁcance = P< 0.05.
Figure 1 Agarose electrophoresis of the PCR products after
cutting with PvuII restriction endonuclease. The bands were
visualized using ethidium bromide and 2% agarose (lanes 2 and 6
represent normal homozygote (MCP-1 2518 AA), lanes 1, 3, 4
and 7 represent homozygote (MCP-1 2518 GG) and lane 5
represents the heterozygote (MCP-1 2518 AG).
40 H.E. Saadany et al.(i) a reduction in the activity of dimethylarginine dimethylami-
nohydrolase (DDAH) a key enzyme governing ADMA (but
not symmetric dimethyl-L-arginine) degradation, which is sen-
sitive to increased oxidative stress present in SLE; (ii) increased
protein arginine type I N-methyltransferase expression due to
oxidative stress [31]; (iii) increased endothelial cell turnover
and the consequent liberation of free ADMA during protein
catabolism; or (iv) decreased DDAH expression due to hypox-
ia within the inﬂamed synovium [6]. High ADMA concentra-
tion may lead to vascular damage by counteracting the
physiological effects of NO, and it thereby promotes athero-
sclerosis. Bo¨ger et al. [32] demonstrated that ADMA might
be a pro-atherogenic molecule by stimulating the secretion of
MCP-1, increasing endothelial superoxide radical formation,
and potentiating monocyte adhesion, which may partly explain
the worse cardiovascular outcome in patients with elevated ser-
um ADMA level. Nevertheless, the exact mechanisms are still
unknown and need further investigation.
In the concurrent study the strength of ADMA for cardio-
vascular risk prediction in SLE was studied in comparison
with 2 novel biomarkers, hs-CRP and MCP-1, as a measure
of the inﬂammatory burden in atherosclerosis.
Increasing evidence points to the inﬂammatory character of
atherosclerosis and several parameters of inﬂammation have
been proposed as cardiovascular risk markers [11].hs-CRP has been considered as a good biomarker of sys-
temic inﬂammation, and might also be the culprit in athero-
sclerosis. Therefore, increased hs-CRP concentration is
associated with higher cardiovascular risk and enhances the
progression of atherosclerosis and also reﬂects arterial wall
inﬂammation [33].
In this study, there was a signiﬁcant increase in hs-CRP le-
vel in SLE patients as compared with healthy controls with
more signiﬁcant increase in SLE patients with IMT P1.00
than, which came in accordance with Barnes et al. [34]. Also
Corrado et al. [10] reported a signiﬁcant correlation between
IMT and hs-CRP which may potentially account for the
complex role of hs-CRP and IMT in the pathogenesis of car-
diovascular events. Roh et al. [35] concluded that measurement
of the serum hs-CRP level is simpler and cheaper than ultraso-
nography. Thus, hs-CRP would be a useful screening marker
for evaluating and estimating the degree of atherosclerosis.
However, Olsen et al. [36] revealed that hs-CRP is only weakly
related to cardiovascular damage after adjustment for tradi-
tional cardiovascular risk factors. Thus, although CRP likely
plays a direct role in the pathogenesis of atherosclerosis, it is
unclear if the CRP levels used to determine risk in the general
population can also be applied in SLE patients [10].
Several lines of evidence suggested that chemokines may
play an important role in the inﬂammatory process and in
the development of atherosclerosis [28]. Over expression of
MCP-1 increased the progression of atherosclerosis. In mouse
models [37], deﬁciency of MCP-1 reduced atherosclerosis [37],
and plasma levels of MCP-1 correlated with monocyte inﬁltra-
tion in atherosclerotic lesions [38]. Consistent with the previ-
ous data, in the present study, the SLE patients have
increased serumMCP-1 level, compared to that of control sub-
jects with more signiﬁcant increase in SLE patients with IMT
P1.00 with a signiﬁcant positive association between plasma
MCP-1 and carotid IMT, which came in agreement with
Brown et al. [39]; also, McMahon and Hahn [28] conﬁrm the
importance of MCP-1 in the development of atherosclerosis
plaque which is emphasized by the ﬁnding that elevated circu-
lating levels of MCP-1 are positively related to increased caro-
tid artery IMT in human. Deo et al. [40] found higher levels of
MCP-1 to be associated with an increased probability of signif-
icant levels of coronary calcium, which is a surrogate measure
for the burden of coronary atherosclerosis. Also MCP-1 may
promote lipid oxidation which is the main contributor to
Biochemical and genetic risk factors for atherosclerosis in systemic lupus erythematosus 41atherogenesis [41]. So, it can be hypothesized that the increased
serum levels of MCP-1 may play a role in the progression of
chronic atherosclerotic lesions in SLE patients. On the basis
of this evidence, MCP-1 should be considered an atheroscle-
rotic factor and a target for selective therapies, such as using
antibodies anti-MCP-1 and anti-MCP-1 gene therapies [42].
Single nucleotide polymorphisms in the MCP-1 regulatory
region (i.e., 2518 G/A substitutions) have been identiﬁed
and shown to affect transcription of the gene. In the present
study signiﬁcant increased frequencies of MCP-1 2518 GG
genotype and G allele existed in SLE patients as compared
with healthy controls, and the percentage of GG genotypes
in SLE with IMT P1 mm (71.5%) is signiﬁcantly higher than
in those with IMT <1 mm (44.4.%), and both groups were
signiﬁcantly higher than controls (5%). Many studies concern-
ing the relationship between MCP-1 gene polymorphism and
inﬂammatory diseases have been performed in the last several
years; Szalai et al. [43] reported that the GG genotype of the
2518 MCP-1 gene is associated with susceptibility to CVD,
Nyquist et al. [14], also reported that this polymorphism was
associated with myocardial infarction and with serum MCP-
1 level in participants of the Framingham Heart Study.
Aguilar et al. [11] demonstrated an association between the
presence of G at position 2518 in the MCP-1 promoter re-
gion and the presence of cutaneous vasculitis among SLE pa-
tients. Also, Tucci et al. [44] show that the A/G and G/G
MCP-1 polymorphisms are associated with a greater likeli-
hood of renal disease in SLE patients. Their explanation is
based on the fact that the 2518 A/G polymorphism in the
promoter region of the MCP-1 gene is functionally important.
It could potentially affect MCP-1 transcription and expression.
In contrast Sa´nchez et al. [45] found no signiﬁcant differences
in the allele and genotype frequencies of the MCP-1 2518 A/
G polymorphism between SLE patients and controls. Also,
Tabara et al. [46] reported that although the plasma level of
MCP-1 showed a signiﬁcant association with carotid IMT,
the 2518 A/G polymorphism did not directly correlate with
carotid IMT. These contradictory results may be due to gene
variations between various countries, as well as among differ-
ent areas in the same country. So the mechanism underlying
this association needs to be elucidated.
However, in the concurrent study signiﬁcant differences in
the IMT and serum levels of HDL-C, ADMA, hs-CRP and
MCP-1 level were found among the different genotypes with
the highest values present in those carrying the G allele (GG
and GA). These results came in accordance Buraczynska
et al. [47], who found that the G allele was associated with
higher levels of serum MCP-1, in both patient groups and
controls.
As mentioned previously, this polymorphism seems to
inﬂuence the transcriptional activity because cells obtained
from individuals with G/G or A/G genotype produce more
MCP-1 protein than cells isolated from individuals with A/A
genotype [48]. Consequently, it would be reasonable to specu-
late that under the same stimulatory conditions, individuals
bearing GG at position 2158 produce more MCP-1 protein
than individuals with the genotype A/A and, in consequence,
could make a stronger inﬂammatory response with higher tis-
sue damage [23]. Also, the concurrent study demonstrated a
signiﬁcant correlation between 2518 A/G polymorphism
and carotid IMT; thus, genetic polymorphisms in theregulatory regions of the MCP-1 gene could be implicated in
the susceptibility or progression of atherosclerosis in SLE.
In the present study, HDL-C, LDL-C, ADMA, hs-CRP,
and MCP-1 (both serum level and MCP-1 2518 AG+GG
polymorphism) were shown to be candidate risk factors for
IMT in simple regression analysis but in multiple regression
analysis, only ADMA and MCP-1 were the strongest indepen-
dent determinants of IMT in SLE patients.
These results came in accordance with Furuki et al. [49]
who revealed that baseline ADMA was the only predictor of
IMT progression after adjustments for age, sex, baseline
IMT, and the four major risk factors plus hyperuricaemia.
In conclusion the present data conﬁrm that ADMA, hs-
CRP, and MCP-1 are identiﬁed as important predictors of ath-
erosclerosis progression and suggest that these factors have
potent damaging effects on the vasculature in SLE patients.
The synergistic effects of higher levels of ADMA, hs-CRP
and MCP-1 in addition to MCP-1 gene polymorphism most
likely contribute to increased IMT as a marker of sub-clinical
atherosclerosis. According to the present ﬁndings individuals
homozygous for G at 2518 of the MCP-1 gene regulatory re-
gion are at increased risk. So screening for MCP-1 polymor-
phisms may be applied to determine the relative risk of
developing atherosclerosis in a patient with an established
diagnosis of SLE.
Kindly suggest: Further studies using larger series might
lead to more signiﬁcant results. There is no speciﬁc treatment
for ADMA and MCP-1. Reversing the effects of increased
ADMA or the reduction of ADMA levels (by increasing the
DDAH) may be meaningful goals for the treatment of endo-
thelial dysfunction in SLE patients.
Therefore, development of a novel therapy targeting
ADMA and MCP-1 may have a potential role in preventing
the progression of increased IMT.References
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